A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes

Tatsuo Fujie, Kouichirou Tahara, Fumiaki Tanaka, Masaki Mori, Kazutou Takesako, Tsuyoshi Akiyoshi

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Although several MAGE-1 peptides have already been identified, the MAGE- 1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides. To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA- A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method. Of the 5 peptides tested, the highest HLA binder (NYKHCFPEI) was able to elicit CTL from unseparated PBMC by stimulation with freshly isolated, peptide-pulsed PMBC as antigen-presenting cells (APC) and by also using interleukin 7 and keyhole-limpet hemocyanin for a primary culture. The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-1-restricted manner. By using the MAGE-1/HLA- A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors.

Original languageEnglish
Pages (from-to)169-172
Number of pages4
JournalInternational Journal of Cancer
Volume80
Issue number2
DOIs
Publication statusPublished - Jan 18 1999

Fingerprint

HLA-A24 Antigen
Cytotoxic T-Lymphocytes
Peptides
Neoplasms
Blood Cells
Interleukin-7
Antigen-Presenting Cells
Immunotherapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. / Fujie, Tatsuo; Tahara, Kouichirou; Tanaka, Fumiaki; Mori, Masaki; Takesako, Kazutou; Akiyoshi, Tsuyoshi.

In: International Journal of Cancer, Vol. 80, No. 2, 18.01.1999, p. 169-172.

Research output: Contribution to journalArticle

Fujie, Tatsuo ; Tahara, Kouichirou ; Tanaka, Fumiaki ; Mori, Masaki ; Takesako, Kazutou ; Akiyoshi, Tsuyoshi. / A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. In: International Journal of Cancer. 1999 ; Vol. 80, No. 2. pp. 169-172.
@article{74097cdb194747cea7980b8f2628197e,
title = "A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes",
abstract = "Although several MAGE-1 peptides have already been identified, the MAGE- 1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides. To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA- A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method. Of the 5 peptides tested, the highest HLA binder (NYKHCFPEI) was able to elicit CTL from unseparated PBMC by stimulation with freshly isolated, peptide-pulsed PMBC as antigen-presenting cells (APC) and by also using interleukin 7 and keyhole-limpet hemocyanin for a primary culture. The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-1-restricted manner. By using the MAGE-1/HLA- A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors.",
author = "Tatsuo Fujie and Kouichirou Tahara and Fumiaki Tanaka and Masaki Mori and Kazutou Takesako and Tsuyoshi Akiyoshi",
year = "1999",
month = "1",
day = "18",
doi = "10.1002/(SICI)1097-0215(19990118)80:2<169::AID-IJC1>3.0.CO;2-P",
language = "English",
volume = "80",
pages = "169--172",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes

AU - Fujie, Tatsuo

AU - Tahara, Kouichirou

AU - Tanaka, Fumiaki

AU - Mori, Masaki

AU - Takesako, Kazutou

AU - Akiyoshi, Tsuyoshi

PY - 1999/1/18

Y1 - 1999/1/18

N2 - Although several MAGE-1 peptides have already been identified, the MAGE- 1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides. To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA- A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method. Of the 5 peptides tested, the highest HLA binder (NYKHCFPEI) was able to elicit CTL from unseparated PBMC by stimulation with freshly isolated, peptide-pulsed PMBC as antigen-presenting cells (APC) and by also using interleukin 7 and keyhole-limpet hemocyanin for a primary culture. The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-1-restricted manner. By using the MAGE-1/HLA- A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors.

AB - Although several MAGE-1 peptides have already been identified, the MAGE- 1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides. To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA- A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method. Of the 5 peptides tested, the highest HLA binder (NYKHCFPEI) was able to elicit CTL from unseparated PBMC by stimulation with freshly isolated, peptide-pulsed PMBC as antigen-presenting cells (APC) and by also using interleukin 7 and keyhole-limpet hemocyanin for a primary culture. The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-1-restricted manner. By using the MAGE-1/HLA- A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=0033579910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033579910&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0215(19990118)80:2<169::AID-IJC1>3.0.CO;2-P

DO - 10.1002/(SICI)1097-0215(19990118)80:2<169::AID-IJC1>3.0.CO;2-P

M3 - Article

C2 - 9935194

AN - SCOPUS:0033579910

VL - 80

SP - 169

EP - 172

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 2

ER -